San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Ansun Biopharma is raising $100,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nancy Chang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ansun Biopharma

Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.

To learn more about Ansun Biopharma, visit http://www.ansunbiopharma.com/

Contact:
Nancy Chang, Chief Executive Officer
858-452-2631

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved